India, July 17 -- Clearside Biomedical, Inc. (CLSD) dropped 24.73 percent to $0.63 after the company revealed plans to explore strategic alternatives to advance its suprachoroidal space delivery platform and drug pipeline. The review, supported by Piper Sandler, could include asset sales, licensing, partnerships, mergers, or other transactions.
The stock traded between $0.3201 and $0.8383, with volume spiking to 2.8 million shares versus an average of 233,315 on the Nasdaq. Clearside's 52-week range stands at $0.3201 to $1.65.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....